Prothena has several interesting drug candidates for Alzheimer’s, Parkinson’s and two rare diseases. The company has different partnerships, over $3 billion in potential milestone payments, and ...

Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So I think there's a lot of exciting ...